MILAN, Italy, April 14 /PRNewswire/ -- Eurand, a specialty pharmaceutical company, announced today that it has signed a research agreement with the University of Urbino (Italy) Biotechnology Centre to evaluate a potential new anticancer compound derived from indol-3-carbinol, a natural substance present in cruciferous vegetables.
Under the terms of the agreement, Eurand and the University of Urbino will collaborate to develop and evaluate the efficacy of the orally administered compound in the treatment of a broad range of cancers. The University of Urbino, which discovered the compound, will be responsible for its synthesis and pre-clinical evaluation. Eurand will be responsible for the development of the product and will use its proprietary solubility enhancement technology Biorise(R) to optimise the absorption profile of the drug. Eurand has worldwide exclusive rights to the compound and would fund future development and commercialisation upon exercise of its option. If exercised, Eurand will pay the University of Urbino success-related milestones and royalties on any future sales of the product.
Gearoid Faherty, Chief Executive Officer of Eurand, commented, “Eurand is excited about this research project and believes that collaborations of this type between universities and industry can be of significant benefit to both. Eurand is actively engaged in discussions with a number of partners for the in-licencing of compounds and we consider this to be an important element of our internal product development strategy. We have recently established a dedicated team to the in-licencing of such compounds and to the establishment of collaborations such as this most recent one with the University of Urbino.”
About Eurand
Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The Company specializes in bioavailability enhancement of poorly soluble drugs, modified release and taste masking and is current developing a pipeline of products based on its proprietary Biorise(R) technology. Eurand also works with many of the world’s leading pharmaceutical and biotechnology companies to develop enhanced forms of their existing products and development compounds. Eurand’s principal operating offices are in Milan, Italy while Eurand’s US business is directed from Eurand Inc. in Vandalia, Ohio. The Company has research, development and manufacturing facilities in Italy, the United States and France.
Eurand
CONTACT: Gearoid Faherty, CEO, Eurand, Inc., (Italy) - +39-02-954281,bizdev@eurand.com
Web site: http://www.eurand.com/
